New milestones achieved in fluoroquinolone safety

Pharmacotherapy

Volumn 21, Issue 3, 2001, Pages 358-360

  Tillotson, Glenn S ^a   Rybak, Michael J ^b  

^a NEW YORK UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC THERAPY; CARDIOTOXICITY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; IMMUNOPATHOLOGY; INFECTION; NAUSEA; PHOTOTOXICITY; QT INTERVAL; REVIEW; TASTE DISORDER; VAGINITIS; VERTIGO; VOMITING;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS;

EID: 0035099028     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.3.358.34205     Document Type: Review

References (17)

1. Trovafloxacin-associated eosinophilic hepatitis
2. Quinolone-induced QT interval prolongation: A-not-so-unexpected class effect
3. Comparative tolerability of the newer fluoroquinolone antibacterials
4. Temafloxacin syndrome: Review of 95 cases
5. FDC Report 1999. FDA/Pharma task force to assess QT risk by preclinical markers
6. A novel approach to postmarketing surveillance: The Tequin Clinical Experience Study
7. Safely and tolerability of gatifloxacin, an advanced generation 8 methoxy fluoroquinolone
8. Clinical efficacy and safety of gatifloxacin in S. pneumoniae community-acquired pneumonia: Initial report from TeqCES
9. Safety update of moxifloxacin: A current review of clinical trials and post-marketing observational studies
10. Treatment of acute exacerbations of chronic bronchitis: A Spanish experience
11. Safety of gemifloxacin in patients aged > 65 years with respiratory and urinary tract infections
12. Safety of moxifloxacin
13. Novelties in the field of anti-infective compounds in 1999